1. Completed clinical trials of immune checkpoint inhibitors in SCLC.

Clinical trial	Phase	Agent	No.	ORR (%)	DOR (month)	Median PFS (month)	Median OS (month)	Reference
SCLC, small cell lung cancer; ORR, objective response rate; DOR, duration of response; PFS, progression-free survival; OS, overall survival.
First-line
IMpower133	III	Atezolizumab vs. placebo	201 vs. 202	62.7 vs. 65.4	4.2 vs. 3.9	5.2 vs. 4.3	12.3 vs. 10.3	(15)
CA184-041	II	Ipilimumab	130	32 vs. 57 vs. 49	−	5.2 vs. 3.9 vs. 5.2	9.1 vs. 12.9 vs. 9.9	(16)
NCT01331525	II	Ipilimumab	42	72.4	−	6.9	17.0	(17)
CA184-156	III	Ipilimumab	566 vs. 566	62 vs. 62	4.01 vs. 3.45	4.6 vs. 4.4	11 vs. 10.9	(18)
Second-line and beyond
NCT01375842	Ia	Atezolizumab 15 mg/kg vs. 1,200 mg	17	6 vs. 24	−	1.5	5.9	(19)
KEYNOTE-028	Ib	Pembrolizumab	24	33.3	19.4	1.9	9.7	(9)
KEYNOTE-158	II	Pembrolizumab	107	18.7	−	2.0	8.7	(20)
CheckMate-032	I/II	Nivolumab vs. Nivo+ipili	149 vs. 96	11.6 vs. 21.9	15.8 vs. 10.0	1.5 vs. 1.4	4.7 vs. 5.7	(21,22)
NCT02261220	I/II	Durvalumab + tremelimumab	30	13.3	−	1.8	7.9	(23)
Switch maintenance treatment
NCT02359019	II	Pembrolizumab	45	11.1	−	1.4	9.6	(24)